Study M1136

Study name

Xu P 2022

Title

[Network pharmacological study and experimental verification of punicalagin in treatment of depression]

Overall design

The aim of this study was to verify the effect and potential mechanism of punicalagin in the treatment of the chronic unpredictable mild stress (CUMS) model of depression. C57BL/6 mice were divided into the following 5 groups: (1) control group, (2) CUMS group, (3) CUMS + low dose of punicalagin group (stressor plus punicalagin treatment at the dose of 12.5 mg/kg), (4) CUMS + middle dose of punicalagin group (stressor plus punicalagin treatment at the dose of 25 mg /kg), and (5) CUMS + high dose of punicalagin group (stressor plus punicalagin treatment at the dose of 50 mg/kg). The CUMS stress procedure lasted for 4 weeks, and drugs were administered via intragastric once per day for 45 days. The content of neurotransmitters in hippocampus was detected by liquid chromatography-mass spectrometry (n = 12 for each group).

Study Type

Type1;

Type2;

Data available

Unavailable

Organism

Mouse; C57BL/6 mouse;

Categories of depression

Animal model; Chronic mild stress model; Chronic mild stress model;

Criteria for depression

Not reported

Sample size

60

Tissue

Central; Brain; Hippocampus;

Platform

MS-based; LC-MS: Agilent 6460 LC-MS;

PMID

N/A

DOI

10.12360/CPB202109029

Citation

Xu P, Huang SY, Guo HM, et al. [Network pharmacological study and experimental verification of punicalagin in treatment of depression]. Chinese Pharmacological Bulletin 2022;38(5):755-60. (Article in Chinese)

Metabolite

Serotonin;

Dopamine;